HUTCHMED (China) (HCM) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Viatris (VTRS) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 76.6% versus a loss of 12.0%. Over five years, VTRS leads with a +31.1% price change compared with -56.3% for HCM. Viatris is the larger company by market cap ($20.26 billion vs $2.45 billion), about 8.3 times the size.
On valuation, Viatris trades at a lower forward P/E (6.6x vs 54.4x for HUTCHMED (China)). Viatris pays a dividend yielding 2.72%, while HUTCHMED (China) does not currently pay one. HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | VTRS |
|---|---|---|
| Share price | $14.10 | $17.64 |
| Market cap | $2.45B | $20.26B |
| 1-day change | +3.15% | +1.15% |
| YTD return | +5.78% | +41.69% |
| 1-year return | -11.99% | +76.58% |
| 5-year return | -56.35% | +31.05% |
| P/E ratio (TTM) | 141.00 | — |
| Forward P/E | 54.40 | 6.60 |
| EPS (TTM) | $0.10 | $-0.36 |
| Dividend yield | 0.00% | 2.72% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $548.51M | $14.30B |
| Revenue growth (YoY) | -12.96% | -2.98% |
| Net income (latest FY) | $456.91M | $-3.51B |
| Gross margin | 38.68% | 35.06% |
| Operating margin | -7.14% | -18.62% |
| Net margin | 83.30% | -24.58% |
| 52-week high | $16.33 | $18.43 |
| 52-week low | $9.77 | $9.73 |
| Distance from 52-week high | -13.66% | -4.29% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +56.10% | +11.68% |
| Average volume | 68.22K | 9.27M |
| Shares outstanding | 173.81M | 1.15B |
| Employees | 1,790 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Viatris is about 8.3 times larger than HUTCHMED (China) by market value ($20.26B vs $2.45B).
- VTRS has outperformed HCM by 88.6 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.72% vs 0.00%).
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Viatris grew revenue faster in its latest fiscal year (-2.98% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
HCM vs VTRS FAQ
Which is bigger, HUTCHMED (China) or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $20.26B compared with $2.45B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or VTRS?
VTRS returned +76.58% over the past 12 months, compared with -11.99% for HCM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, HUTCHMED (China) or Viatris?
Viatris pays a dividend yielding 2.72%, while HUTCHMED (China) does not currently pay a regular dividend.
Are HUTCHMED (China) and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.